Atezolizumab and <i>nab</i>-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study

2021287 citationsJournal Articlebronze Open Access

Authors

Leisha A. Emens · Magee-Womens Hospital

Luciana Molinero

Sherene Loi · The University of Melbourne

Hope S. Rugo · University of California, San Francisco

Andreas Schneeweiß · German Cancer Research Center

Véronique Dièras · Centre Eugène Marquis

Hiroji Iwata · Aichi Cancer Center

Abstract

Although A+nP was more efficacious in patients with richer tumor immune microenvironment, clinical benefit was only observed in patients whose tumors were PD-L1 IC+.

Topics & Keywords

Cancer Immunotherapy and Biomarkers Advanced Breast Cancer Therapies Cancer Genomics and Diagnostics

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JNCI Journal of the National Cancer Institute

Volume 113, Issue 8, pp. 1005-1016

DOI: 10.1093/jnci/djab004

Field-Weighted Citation Impact: 20.94